Hillenbrand (HI)
(Delayed Data from NYSE)
$42.68 USD
-0.31 (-0.72%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $42.71 +0.03 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Price, Consensus and EPS Surprise
HI 42.68 -0.31(-0.72%)
Will HI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HI
Huntington (HII) Clinches Contract to Aid DDG 51 Assault Ships
Hillenbrand (HI) Q4 Earnings Beat Estimates, Revenues Up Y/Y
HI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights W.W. Grainger, MSC Industrial, Hillenbrand and DMC Global
4 Industrial Services Stocks Countering Industry Headwinds
Hillenbrand (HI) Loses -9.82% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for HI
Hims & Hers down 6% following report on weight loss drug
Hims & Hers down 6% following report on 'shady supplier' for weight loss drug
Him & Hers down 6% following report on 'shady supplier' for weight loss drug
Morning Brew: CrowdStrike Joins S&P 500, Micron's Target Raised, Alimera Sciences Acquired
Oppenheimer spotlights top buy/sell ideas for mid and small cap names